Evidence map›Paper›PMID 24649209›Full record

ArticleMolecular and clinical oncology2013

Rituximab used in three cases with relapsed non-Hodgkin's lymphoma.

Murat Elli, Sema Yilmaz, Ramazan Aydin, Sadriye Murat, Meltem Ceyhan Bilgici, Ayhan Dagdemir

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Murat ElliDepartments of Pediatric Hematology/Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
Sema YilmazDepartments of Pediatric Hematology/Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
Ramazan AydinRadiology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
Sadriye MuratPediatrics, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
Meltem Ceyhan BilgiciRadiology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
Ayhan DagdemirDepartments of Pediatric Hematology/Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
Ondokuz Mayıs University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been used to improve survival rates in children with relapsed or refractory B-NHL. CD20 is expressed in >98% of childhood B-NHL and a chimeric anti-CD20 monoclonal antibody, rituximab, is increasingly being used at relapse. The aim of the present study was to determine the efficacy of rituximab on relapsed B-NHL. Three B-NHL cases were treated successfully with a combination of intensive chemotherapy protocol plus rituximab.

Indexed as

childrennon-Hodgkin’s lymphomarelapserituximab

Identifiers

PMID24649209
PMCPMC3915537
OpenAlexW2065497648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.